Cabaletta Bio to Present DSG3-CAART Clinical Data and MuSK-CAART Preclinical Data at…
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell…